Overview

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to determine the effectiveness of giving interferon alfa after chemotherapy and peripheral stem cell transplantation to patients who have stage III or stage IV multiple myeloma and who have been treated with high-dose melphalan.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Tennessee
Treatments:
Cyclophosphamide
Dexamethasone
Interferon-alpha
Interferons
Melphalan
Sargramostim
Criteria
DISEASE CHARACTERISTICS: See General Eligibility Criteria

PATIENT CHARACTERISTICS: Age: 19 to 64 Performance Status: Zubrod 0-3 Hematopoietic: Not
specified Hepatic: Bilirubin less than 2 mg/dL SGOT and SGPT less than 3 times normal
Alkaline phosphatase less than 3 times normal Renal: Creatinine clearance at least 60
mL/min Cardiovascular: Cardiac ejection fraction at least 50% Pulmonary: No history of
severe chronic obstructive lung disease No history of recurrent pulmonary emboli Other: Not
pregnant or nursing Effective contraception should be practiced by fertile patients No
history of diabetes mellitus complicated by ketoacidosis No history of depression or
psychosis No history of autoimmune disorders No concurrent thyroid disorders unable to be
maintained on replacement therapy No prior hypersensitivity to interferon alfa-2b

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 12
months of prior alkylator therapy Endocrine Therapy: Not specified Radiotherapy: Not
specified Surgery: Not specified